

AD _____

Award Number: DAMD17-89-C-9050

TITLE: A Medical Research and Evaluation Facility and Studies
Supporting the Medical Chemical Defense Program

PRINCIPAL INVESTIGATOR: Carl T. Olson, DVM, Ph.D.

CONTRACTING ORGANIZATION: Battelle Memorial Institute
Columbus, Ohio 43201-2693

REPORT DATE: November 1998

TYPE OF REPORT: Final, Task 97-56

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20000323 080

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE February 2000	3. REPORT TYPE AND DATES COVERED Final, Task 97-56	
4. TITLE AND SUBTITLE A Medical Research and Evaluation Facility and Studies Supporting the Medical Chemical Defense Program			5. FUNDING NUMBERS DAMD17-89-C-9050	
6. AUTHOR(S) Carl T. Olson, DVM, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Battelle Memorial Institute Columbus, Ohio 43201-2693 E-MAIL: olsonc@battelle.org			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words)				
14. SUBJECT TERMS Nerve Agents, Antidotes, CD Agents, CSM Sheep, Vesicants, Decontamination, Skin Protection, Desert Shield, BL3, BD, Advanced Development, RADV, CD, RADIV				15. NUMBER OF PAGES 4
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

___ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Carl T. Olson, DVM, Ph.D.

PI - Signature

Date

Internal Distribution

Estep, James
Hayes, Timothy
Bowen, Gregory

Date November 4, 1998
To Col. Richard Stotts
Army Medical Research and Materiel
Command
From Michael Crenshaw *MC*
Subject Contract DAMD17-89-C-9050, Task 97-56

This memo serves as an unclassified summary report for Task 97-56 under Contract DAMD17-89-C-9050. A classified final report has been prepared and awaits delivery instructions. The final report contains data and detailed discussions to demonstrate that the goals of this program have been met.

The goals of this program were to deliver 5-10 grams each of Compound II and Compound IV. Each compound was to have a purity of 95% or greater as determined by gas chromatography-mass spectrometry (GC/MS) and nuclear magnetic resonance spectroscopy (NMR).

On 11 February 1998, 7.88 grams of Compound II with a purity of 99.3% (lot no. 47775-64-06) and 7.37 grams of Compound IV with a purity of 96.5% (lot no. 47775-76-25) were delivered to Battelle's Medical Research and Evaluation Facility, West Jefferson, Ohio. Supporting spectroscopic data was also sent on the same day.